These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12528002)

  • 1. Loss of color vision during long-term treatment with pramipexole.
    Müller T; Przuntek H; Kuhlmann A
    J Neurol; 2003 Jan; 250(1):101-2. PubMed ID: 12528002
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole-induced psychosis in Parkinson's disease.
    Li CT; Tsai SJ; Hwang JP
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):245. PubMed ID: 18412854
    [No Abstract]   [Full Text] [Related]  

  • 6. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 7. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole marketed for Parkinson's disease.
    Am J Health Syst Pharm; 1997 Sep; 54(17):1922. PubMed ID: 9290885
    [No Abstract]   [Full Text] [Related]  

  • 9. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirapex: pramipexole dihydrochloride tablets.
    Claussen DW
    Gastroenterol Nurs; 1999; 22(6):266-7. PubMed ID: 10855124
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic cluster headache responsive to pramipexole.
    Palmieri A
    Cephalalgia; 2006 Jun; 26(6):761-2. PubMed ID: 16686920
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian drugs and "sleep attacks".
    Moller H
    CMAJ; 2001 Apr; 164(7):1038-9, 1042-3. PubMed ID: 11314438
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep episodes in Parkinson's disease: a wake-up call.
    Frucht SJ; Greene PE; Fahn S
    Mov Disord; 2000 Jul; 15(4):601-3. PubMed ID: 10928569
    [No Abstract]   [Full Text] [Related]  

  • 16. Modafinil treatment of pramipexole-associated somnolence.
    Hauser RA; Wahba MN; Zesiewicz TA; McDowell Anderson W
    Mov Disord; 2000 Nov; 15(6):1269-71. PubMed ID: 11104221
    [No Abstract]   [Full Text] [Related]  

  • 17. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathological gambling associated with pramipexole use in Parkinson's disease].
    Lester J; Gonzalez-Aleman G; Zuniga-Ramirez C; Diaz-Pascuali SP; Raina-Castellino GB; Micheli-Gould F
    Rev Neurol; 2006 Sep 1-15; 43(5):316-8. PubMed ID: 16941434
    [No Abstract]   [Full Text] [Related]  

  • 19. Weight loss is often a problem in late PD.
    Jacques C; Davies R; Friedman JH
    J Neurosci Nurs; 1998 Dec; 30(6):342. PubMed ID: 9949971
    [No Abstract]   [Full Text] [Related]  

  • 20. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease.
    Katz KA; Cotsarelis G; Gupta R; Seykora JT
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.